Allergic bronchopulmonary aspergillosis is a hypersensitivity reaction to bronchial colonization by Aspergillus fumigatus mold, typically affecting patients with asthma or cystic fibrosis.
Exposure of atopic people to fungal spore elements results in the formation of immunoglobulin E and immunoglobulin G antibodies.
Presents as asthma complicated by bronchial obstruction, fever, malaise, expectoration of brownish mucus plugs, peripheral blood eosinophilia, and hemoptysis.
Treatment involves environmental control measures, corticosteroids, and azole antifungals.
Early detection and treatment can prevent the development of bronchiectasis or pulmonary fibrosis that otherwise occurs in the later stages of the disease.
Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction to mold that occurs when bronchi become colonized by Aspergillus fumigatus in an otherwise immunocompetent person. Patients usually have a prior diagnosis of atopy, asthma, or cystic fibrosis. Exposure of an atopic person to fungal elements results in the formation of IgE and IgG antibodies. Typically, the patient presents with bronchial obstruction, airway inflammation, and mucoid impaction that can lead to bronchiectasis, fibrosis, and respiratory compromise.
History and exam
Cristine Radojicic, MD
Department of Pulmonary, Allergy and Critical Care
CR is on the Advisory Board for CSL Behring and the Speakers Bureau for BioCryst.
Martin Schöni, MD
Department of Pediatrics
University of Bern
MS declares that he has no competing interests.
Jordan Fink, MD
Professor of Pediatrics
Medical College of Wisconsin
JF is an author of a number of references cited in this topic.
Use of this content is subject to our disclaimer